Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and Evgen Pharma to explore treatment for osteoarthritis
Researchers will investigate the potential of the drug SFX-01 as a treatment for osteoarthritis.
Work will build on a previous collaboration

The RVC and Evgen pharma have secured funding from the Biotechnology and Biological Sciences Research Council (BBSRC) for a four-year PhD studentship focused on investigating treatment for osteoarthritis.

The Industrial Co-operative Awards in Science & Technology (CASE) PhD Studentship will allow researchers to investigate the potential of the drug SFX-01 as a treatment for the disease, which affects almost 9 million people across the UK.

The work will build on a previous collaboration, which showed that mice with spontaneously-arising osteoarthritis demonstrated significantly improved bone architecture and preservation of normal movement following three months of SFX-01 treatment.

Professor Andrew Pitsillides, who led the study, said: “Myself and my colleagues Drs Isabel Orriss and Behzad Javaheri in the RVC’s Skeletal Biology Group are very excited by the prospect of working with Evgen Pharma to identify the cellular and molecular targets by which SFX-01 exerts its beneficial actions in osteoarthritis.”

Evgen Pharma is a clinical stage drug development company that focuses on the treatment of cancer and neurological conditions.

CEO Dr Stephen Franklin commented: “As a Company, we remain focused on the delivery of our current Company sponsored clinical trials and our strategic focus is in cancer and neurology. 

“We will, however, provide SFX-01 to a limited number of world leading academics and clinical groups that wish to investigate SFX-01 in alternative therapeutic areas if they can demonstrate a robust clinical plan, source their own non-dilutive grant funding and we retain commercialisation rights.

“We, and the RVC, are delighted that the BBSRC is funding this programme and it is another step towards the possibility of a future, grant funded, clinical trial on SFX-01 in osteoarthritis”. 

Become a member or log in to add this story to your CPD history

Blue Dog Programme wins WSAVA One Health award

News Story 1
 An educational initiative to help children interact safely with dogs has been awarded the WSAVA’s 2017 Global One Health Award.

The Blue Dog Programme offers an array of educational resources for children, parents and school teachers, including an engaging website, fact sheets, DVD and an accompany book for parents.

The award will be accepted by Professor Tiny de Keuster, a European veterinary specialist in behavioural medicine and founder of the programme, during WSAVA World Congress 2017.  

News Shorts
VMD stakeholder workshops to discuss Brexit implications

The Veterinary Medicines Directorate (VMD) has announced that it is to hold stakeholder group workshops to discuss the implications of EU exit.

The workshops will be held during Autumn 2017 and will discuss topics such as the prescribing cascade, pharmacovigilance and inspection of non-UK based manufacturers.

To register your interest, send an email to events@vmd.defra.gsi.gov.uk, including any topics, in order of preference, that you would like to be discussed.